A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

Susanna Esposito; Paola Marchisio; Filippo Ansaldi; Sonia Bianchini; Michela Pacei; Elena Baggi; Daria Trabattoni; Giancarlo Icardi; Nicola Principi

doi:10.1016/j.vaccine.2010.07.041

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

Susanna Esposito, Paola Marchisio, Filippo Ansaldi, Sonia Bianchini, Michela Pacei, Elena Baggi, Daria Trabattoni, Giancarlo Icardi, Nicola Principi

Research output: Contribution to journal › Article › peer-review

Abstract

This study evaluated the immunogenicity of a double dose of the seasonal virosomal-adjuvanted influenza vaccine (Inflexal V, Crucell, The Netherlands) in 65 previously unvaccinated children aged less than 3 years: 43 received double doses (two doses of 0.50. mL 4 weeks apart) and 22 standard doses (two doses of 0.25. mL 4 weeks apart). Both treatments evoked a response that satisfied the EMEA criteria for adequate immunogenicity for all three vaccine strains, but the double dose had a significantly greater effect on all of the studied parameters of humoral and cell-mediated immune response (p

Original language	English
Pages (from-to)	6137-6144
Number of pages	8
Journal	Vaccine
Volume	28
Issue number	38
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.041
Publication status	Published - Aug 2010

Keywords

Children
Immunogenicity
Influenza
Influenza vaccine
Reactogenicity
Virosomal

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)

Access to Document

10.1016/j.vaccine.2010.07.041

Cite this

Esposito, S., Marchisio, P., Ansaldi, F., Bianchini, S., Pacei, M., Baggi, E., Trabattoni, D., Icardi, G., & Principi, N. (2010). A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine, 28(38), 6137-6144. https://doi.org/10.1016/j.vaccine.2010.07.041

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. / Esposito, Susanna; Marchisio, Paola; Ansaldi, Filippo; Bianchini, Sonia; Pacei, Michela; Baggi, Elena; Trabattoni, Daria; Icardi, Giancarlo; Principi, Nicola.

In: Vaccine, Vol. 28, No. 38, 08.2010, p. 6137-6144.

Research output: Contribution to journal › Article › peer-review

Esposito, S, Marchisio, P, Ansaldi, F, Bianchini, S, Pacei, M, Baggi, E, Trabattoni, D, Icardi, G & Principi, N 2010, 'A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months', Vaccine, vol. 28, no. 38, pp. 6137-6144. https://doi.org/10.1016/j.vaccine.2010.07.041

Esposito, Susanna ; Marchisio, Paola ; Ansaldi, Filippo ; Bianchini, Sonia ; Pacei, Michela ; Baggi, Elena ; Trabattoni, Daria ; Icardi, Giancarlo ; Principi, Nicola. / A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. In: Vaccine. 2010 ; Vol. 28, No. 38. pp. 6137-6144.

@article{da0c328ee2a641e1afb3efd54dcc6b42,

title = "A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months",

abstract = "This study evaluated the immunogenicity of a double dose of the seasonal virosomal-adjuvanted influenza vaccine (Inflexal V, Crucell, The Netherlands) in 65 previously unvaccinated children aged less than 3 years: 43 received double doses (two doses of 0.50. mL 4 weeks apart) and 22 standard doses (two doses of 0.25. mL 4 weeks apart). Both treatments evoked a response that satisfied the EMEA criteria for adequate immunogenicity for all three vaccine strains, but the double dose had a significantly greater effect on all of the studied parameters of humoral and cell-mediated immune response (p",

keywords = "Children, Immunogenicity, Influenza, Influenza vaccine, Reactogenicity, Virosomal",

author = "Susanna Esposito and Paola Marchisio and Filippo Ansaldi and Sonia Bianchini and Michela Pacei and Elena Baggi and Daria Trabattoni and Giancarlo Icardi and Nicola Principi",

year = "2010",

month = aug,

doi = "10.1016/j.vaccine.2010.07.041",

language = "English",

volume = "28",

pages = "6137--6144",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "38",

}

TY - JOUR

T1 - A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

AU - Esposito, Susanna

AU - Marchisio, Paola

AU - Ansaldi, Filippo

AU - Bianchini, Sonia

AU - Pacei, Michela

AU - Baggi, Elena

AU - Trabattoni, Daria

AU - Icardi, Giancarlo

AU - Principi, Nicola

PY - 2010/8

Y1 - 2010/8

N2 - This study evaluated the immunogenicity of a double dose of the seasonal virosomal-adjuvanted influenza vaccine (Inflexal V, Crucell, The Netherlands) in 65 previously unvaccinated children aged less than 3 years: 43 received double doses (two doses of 0.50. mL 4 weeks apart) and 22 standard doses (two doses of 0.25. mL 4 weeks apart). Both treatments evoked a response that satisfied the EMEA criteria for adequate immunogenicity for all three vaccine strains, but the double dose had a significantly greater effect on all of the studied parameters of humoral and cell-mediated immune response (p

AB - This study evaluated the immunogenicity of a double dose of the seasonal virosomal-adjuvanted influenza vaccine (Inflexal V, Crucell, The Netherlands) in 65 previously unvaccinated children aged less than 3 years: 43 received double doses (two doses of 0.50. mL 4 weeks apart) and 22 standard doses (two doses of 0.25. mL 4 weeks apart). Both treatments evoked a response that satisfied the EMEA criteria for adequate immunogenicity for all three vaccine strains, but the double dose had a significantly greater effect on all of the studied parameters of humoral and cell-mediated immune response (p

KW - Children

KW - Immunogenicity

KW - Influenza

KW - Influenza vaccine

KW - Reactogenicity

KW - Virosomal

UR - http://www.scopus.com/inward/record.url?scp=77955663597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955663597&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.07.041

DO - 10.1016/j.vaccine.2010.07.041

M3 - Article

C2 - 20670909

AN - SCOPUS:77955663597

VL - 28

SP - 6137

EP - 6144

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

ER -

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this